Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Comment by Floridas2000on Mar 15, 2017 11:38am
132 Views
Post# 25982340

RE:RE:RE:RE:RE:RE:ARLZ will be discounted to cash

RE:RE:RE:RE:RE:RE:ARLZ will be discounted to cashI try not to sell when everyone is selling or buy when everyone is buying.  When a market goes into a frenzy they always overdo it on the up (SJL) and downside (ARLZ).  Investors stayed invested in ARLZ because of the sales team and acceptance of the drug along with becoming profitable this year.  It won't happen this year.  They got punished.  But punishing it to cash too much since good news was ignored.  The push to sell ARLZ in Europe.  Performance of other drugs.  The increase revenue yoy and qoq (yes I know last year's numbers were only for Pozen).  I am still curious how Tribute's stable of drugs are doing.  They don't divide out the numbers but they should be growing.

I am sitting because it's free money for me and I sold half when it doubled with Tribute.  I am hoping this is a wake up call for Adams since he's heavily invested in ARLZ and is losing a lot of money.  Not pleased at all but I will be patient until I'm not.  Good luck to all.
<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse